Proactive Investors - Run By Investors For Investors

Avacta Group - Capital Network: Preliminary Results

Avacta’s FY 2017 Preliminary Results: Reagents and therapeutics programs all on track
Avacta Group - Capital Network: Preliminary Results


  • Avacta’s Affimer® technology is a proprietary alternative to antibodies with key technical and commercial benefits
  • Avacta is building a pipeline of Affimer drugs for immuno-oncology and growing revenues based on a licensing model for Affimer reagents
  • Excellent progress in both parts of the business during the reporting period substantially de-risking the opportunity
  • A pipeline of potential valuable and licensable drugs is being built and the company is targeting first clinical trials in 2019
  • A sum-of-the-parts model now suggests an equity value four times the current market capitalisation



On the 4th October, Avacta Group Plc (LON:AVCT) has reported preliminary results for the fiscal year ending July 2017, including a detailed update on the business.

Overall Avacta Group Plc (LON:AVCT) is delivering according to management's guidance and has made significant progress in both the Affimer reagents' business and the Affimer therapeutics programs (please refer to our initiation report of March 2017 for an overview of Avacta's Affimer technology and business strategy).

As regards the Reagents business, Avacta Group Plc (LON:AVCT) announced in April 2017 that, after a trial period, they have granted a leading diagnostic company exclusive rights to specific Affimer reagents. Although financial details weren't disclosed, this was the first time that Avacta signed an agreement of this nature, representing an important inflection point in de-risking the reagents business.

As such we remove any risk adjustment from our valuation of the Affimer reagents business, which we now value approx. £140mil, from about £110mil before this deal was signed.


Following the release of FY 2017 preliminary results, we have updated our chart showing the key upcoming milestones for Avacta's reagents and therapeutic programs.
Affimer Therapeutics
As regards the further pre-clinical development of the Affimer's immuno-oncology program, we expect Avacta to focus on additional in-vivo PK and toxicity studies and on the preparation of the tech transfer and CMC (chemistry, manufacturing and control) dossier.
We also note that Avacta's collaborations with Moderna, the Sloan Kettering Cancer Center and Glythera are all progressing according to plan and are due updates over the next 12 months.

Affimer reagents
With custom Affimers' order book up 91% y-o-y, we would expect that one or more of the ongoing paid-for evaluations will lead to the finalization of further licensing agreements in the coming quarters.


Full report is available via Capital Network website

Register here to be notified of future AVCT Company articles
View full AVCT profile View Profile

Avacta Group Plc Timeline

Related Researches

November 15 2017
  • Genedrive (LON:GDR) on track to become a commercial stage, point-of-need diagnostics company
  • Launch of Genedrive® Hepatitis C (HCV) test at IFCC World Lab October 2017, with commercial sales expected in the coming quarters (African markets)
  • Distribution agreement signed for HCV test for Asia Pacific
  • Collaboration with the US Defense Department (bio-hazard program) to generate further income (c. $1.9mln) in the current fiscal year
  • Re-launch of Genedrive® MTB (tuberculosis) test is being reassessed
  • Management actively engaged in the disposal of the legacy service business (preclinical research and pharmacogenomics)
  • Cash position of £4.2mln as of 30 September 2017, enough to finance the ongoing business well into fiscal year 2019
  • Our SOTP valuation yields an equity value of c. £24mln, over 3x current market capitalization
April 03 2017

Sphere Medical is launching Proxima 4, the first patient-attached blood gas and electrolytes (BGE) monitoring system on the market, which could transform the way critically ill patients are treated.

March 08 2017

Avacta (AVCT.LON), a UK-based biotechnology company, has developed an innovative proteinscaffold platform, with potential applications in the life sciences research, diagnostic and therapeutic markets.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use